Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work
J&J Veteran To Continue Rebuilding In 2023
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.
You may also be interested in...
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.
The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.